Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.54 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.50 |
| ▸ | CTSD | P07339 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 5/20 | 0.49 |
| ▸ | CTSE | P14091 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7419554 | 1.00 | REN (0.54) | RENNMUR2NMUR1CTSDACE | |
| SCHEMBL7411063 | 0.93 | ACE (0.56) | RENNMUR2ACEACE2 | |
| SCHEMBL8060131 | 0.93 | ACE (0.56) | RENNMUR2ACEACE2 | |
| SCHEMBL8334047 | 0.91 | CALCRL (0.49) | RENNMUR2CTSDCTSEBACE1 | |
| SCHEMBL6374240 | 0.89 | OPRM1 (0.52) | ACEACE2 | |
| SCHEMBL27499487 | 0.85 | REN (0.49) | RENNMUR2NMUR1CTSDACE | |
| SCHEMBL5208748 | 0.84 | CTSD (0.49) | CTSDACECTSEBACE1ACE2 | |
| SCHEMBL7414240 | 0.83 | ACE (0.49) | RENCTSDACECTSEBACE1 | |
| SCHEMBL30788009 | 0.81 | NMUR2 (0.53) | NMUR2NMUR1ACEACE2 | |
| SCHEMBL8330748 | 0.81 | ACE (0.60) | ACEBACE1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596687-B1 | For treatment of many inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-07-22 | — | — | US | claimed |
| US-6239108-B1 | Cell adhesion inhibitors | BIOGEN, INC. | 2001-05-29 | — | — | US | claimed |
| WO-1997003094-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-01-30 | — | — | WO | claimed |
| US-20230255931-A1 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF TISSUE INJURY | MEDREGEN, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20220184043-A1 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH AMD3100 AND TACROLIMUS | MEDREGEN, LLC | 2022-06-16 | — | — | US | disclosed |
| EP-3914599-A1 | NON-IMMUNOSUPPRESSIVE FK506 ANALOGS AND USE THEREOF | The Johns Hopkins University (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210251954-A1 | METHODS OF RECRUITING SDF-PRODUCING MACROPHAGES | MEDREGEN, LLC | 2021-08-19 | — | — | US | disclosed |
| EP-3808368-A2 | TREATMENT METHODS UTILIZING STEM CELL MOBILIZERS AND IMMUNOSUPPRESSIVE AGENTS | Medregen, LLC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10945993-B2 | Methods of recruiting SDF-producing macrophages | MEDREGEN, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210008042-A1 | TREATMENT METHODS UTILIZING STEM CELL MOBILIZERS AND IMMUNOSUPPRESSIVE AGENTS | MEDREGEN LLC (US) | 2021-01-14 | — | — | US | disclosed |
| US-10813917-B2 | Treatment methods utilizing stem cell mobilizers and immunosuppressive agents | MEDREGEN, LLC (US) | 2020-10-27 | — | — | US | disclosed |
| EP-1303492-A2 | AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS ALPHA 4 INTEGRIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020091115-A1 | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002002556-A2 | AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
| US-6248713-B1 | OLIGOPEPTIDE FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BIOGEN, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6239108-B1 | Cell adhesion inhibitors | BIOGEN, INC. | 2001-05-29 | — | — | US | disclosed |
| WO-2000002903-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 2000-01-20 | — | — | WO | disclosed |
| EP-0737204-A4 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORP (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0737204-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995015973-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091115-A1 | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists | ITGA4, ITGA1, ITGB4 | REN 2586/4885NMUR2 849/4885NMUR1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.